We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+30.88%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$149M
AUM Growth
+$1.61M
Cap. Flow
+$7.75M
Cap. Flow %
5.19%
Top 10 Hldgs %
54.08%
Holding
54
New
19
Increased
8
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$7.23M
2
TSHA icon
Taysha Gene Therapies
TSHA
+$7.15M
3
REPL icon
Replimune Group
REPL
+$2.95M
4
HLVX
HilleVax
HLVX
+$2.92M
5
ALKS icon
Alkermes
ALKS
+$2.4M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.17M
2
ARGX icon
argenx
ARGX
+$4.9M
3
CLNN icon
Clene
CLNN
+$3.73M
4
GHRS icon
GH Research
GHRS
+$2.9M
5
TERN
Terns Pharmaceuticals
TERN
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 91.72%
2 Financials 0.33%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
51
Roivant Sciences
ROIV
$26.2B
– –
-220,000
Closed -$2.22M
SVRA icon
52
Savara
SVRA
$1.19B
– –
-198,139
Closed -$633K
MORF
53
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-17,500
Closed -$1M
ISEE
54
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-131,454
Closed -$5.17M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Acuta Capital Partners held 54 positions worth $149M, up 1.1% from $148M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners deployed $7.75M of net new capital in Q3 2023, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was RayzeBio, Inc. Common Stock: 344,571 shares worth $7.65M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 97% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.63M trimmed.

  • Acuta Capital Partners's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 344,571 shares worth $7.65M.
  • Acuta Capital Partners added most to HilleVax in Q3 2023, an estimated $2.92M increase.
  • Acuta Capital Partners's biggest Q3 2023 reduction was Terns Pharmaceuticals, cutting an estimated $2.63M.
  • Acuta Capital Partners fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.17M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $149M portfolio in Q3 2023.
  • Acuta Capital Partners opened 19 new positions and closed 8 in Q3 2023.
  • Acuta Capital Partners's portfolio value rose 1.1% quarter-over-quarter to $149M.

Based on Acuta Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.